
New data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat advanced melanoma showed overall survival of five years in 34% patients, …
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership

